

# William Chey

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4590236/william-chey-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83

papers

3,665

citations

31

h-index

59

g-index

85

ext. papers

4,147

ext. citations

4.9

avg, IF

5.1

L-index

#	Paper	IF	Citations
83	Preliminary development and validation of the Patient-Physician Relationship Scale for physicians for disorders of gut-brain interaction. <i>Neurogastroenterology and Motility</i> , <b>2021</b> , 33, e13976	4	2
82	Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review. <i>Therapeutic Advances in Gastroenterology</i> , <b>2020</b> , 13, 1756284819897531	4.7	11
81	Integrated care for disorders of gut-brain interaction. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 876-877	18.8	1
80	The Impact of a 4-Week Low-FODMAP and mNICE Diet on Nutrient Intake in a Sample of US Adults with Irritable Bowel Syndrome with Diarrhea. <i>Journal of the Academy of Nutrition and Dietetics</i> , <b>2020</b> , 120, 641-649	3.9	25
79	Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea. <i>Neurogastroenterology and Motility</i> , <b>2018</b> , 30, e13331	4	3
78	The gut microbiome and irritable bowel syndrome. <i>F1000Research</i> , <b>2018</b> , 7,	3.6	55
77	Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1319-1328	6.1	21
76	Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 3568-3578	4	23
75	A Systematic Review of the Effects of Polyols on Gastrointestinal Health and Irritable Bowel Syndrome. <i>Advances in Nutrition</i> , <b>2017</b> , 8, 587-596	10	31
74	Fermented Fiber Supplements Are No Better Than Placebo for a Laxative Effect. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 3140-3146	4	22
73	Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2016</b> , 44, 1114-1122	6.1	22
72	Computer-generated vs. physician-documented history of present illness (HPI): results of a blinded comparison. <i>American Journal of Gastroenterology</i> , <b>2015</b> , 110, 170-9	0.7	25
71	A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 426-37	6.1	50
70	Dietary Renaissance in IBS: Has Food Replaced Medications as a Primary Treatment Strategy?. <i>Current Treatment Options in Gastroenterology</i> , <b>2014</b> , 12, 424-40	2.5	25
69	Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 771-9	6.1	82
68	Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 39, 1161-8	6.1	67
67	Factors associated with quality of life among women with fecal incontinence. <i>International Urogynecology Journal</i> , <b>2013</b> , 24, 493-9	2	29

66	Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 49-61	6.1	93
65	Factors associated with symptom severity in women presenting with fecal incontinence. <i>Diseases of the Colon and Rectum</i> , <b>2013</b> , 56, 97-102	3.1	28
64	Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 587-99	6.1	90
63	Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2012</b> , 35, 745-67	6.1	205
62	Type of pain, pain-associated complications, quality of life, disability and resource utilisation in chronic pancreatitis: a prospective cohort study. <i>Gut</i> , <b>2011</b> , 60, 77-84	19.2	194
61	A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 1803-12	0.7	131
60	Characterizing abdominal pain in IBS: guidance for study inclusion criteria, outcome measurement and clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 1192-202	6.1	25
59	Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 1275-91	6.1	49
58	Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule. <i>Neurogastroenterology and Motility</i> , <b>2010</b> , 22, 527-33, e117	4	80
57	The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 859-65	0.7	115
56	The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 313-22	6.1	109
55	Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 684-97	4	15
54	Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 3415-22	4	35
53	Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 329-41	6.1	284
52	Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 29, 1261-72	6.1	74
51	Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 1159-70	6.1	73
50	Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective. <i>Ecological Management and Restoration</i> , <b>2009</b> , 22, 461-6	3	6
49	Treatment patterns and symptom control in patients with GERD: US community-based survey. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 1869-78	2.5	50

48	The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 473-82	6.1	81
47	Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 1249-58	6.1	16
46	Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2008</b> , 2, 497-508	4.2	10
45	Recent developments in the therapy of irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , <b>2008</b> , 17, 117-30	5.9	11
44	Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 186-96	6.1	251
43	Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 443-52	6.1	44
42	Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia. <i>Evidence-Based Medicine</i> , <b>2007</b> , 12, 79		
41	Irritable bowel syndrome: update on colonic neuromuscular dysfunction and treatment. <i>Current Gastroenterology Reports</i> , <b>2006</b> , 8, 273-81	5	15
40	Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 23, 655-68	6.1	11
39	Review article: current and emerging therapies for functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 475-92	6.1	63
38	Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. <i>Expert Opinion on Investigational Drugs</i> , <b>2005</b> , 14, 185-93	5.9	45
37	Effect of acute acoustic stress on anorectal function sensation in healthy human. <i>Neurogastroenterology and Motility</i> , <b>2005</b> , 17, 222-8	4	17
36	Implications for treatment: pH, Helicobacter pylori or alternative approaches?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 21 Suppl 1, 17-8, 21-4	6.1	
35	Evaluation of the Ez-HBT Helicobacter blood test to establish Helicobacter pylori eradication. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2005</b> , 22, 875-80	6.1	10
34	A clinician's guide to managing Helicobacter pylori infection. <i>Cleveland Clinic Journal of Medicine</i> , <b>2005</b> , 72, 109-10, 112-3, 117-8 passim	2.8	9
33	Irritable bowel syndrome - an evidence-based approach to diagnosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19, 1235-45	6.1	44
32	Review article: tegaserod -- the global experience. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 20 Suppl 7, 15-9	6.1	7
31	Review article: uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2004</b> , 19 Suppl 1, 1-8	6.1	23

30	Advances in the management of irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , <b>2003</b> , 5, 468-75	5	20
29	Lansoprazole and Esomeprazole in Symptomatic GERD. <i>Clinical Drug Investigation</i> , <b>2003</b> , 23, 69-84	3.2	28
28	Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. <i>American Journal of Gastroenterology</i> , <b>2003</b> , 98, 301-7	0.7	28
27	Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2002</b> , 16, 1491-501	6.1	42
26	Effect of meal size and test duration on gastric emptying and gastric myoelectrical activity as determined with simultaneous [ <sup>13</sup> C]octanoate breath test and electrogastronomy in normal subjects using a muffin meal. <i>Digestive Diseases and Sciences</i> , <b>2001</b> , 46, 2643-50	4	22
25	Can endoscopic ultrasound or magnetic resonance cholangiopancreatography replace ERCP in patients with suspected biliary disease? A prospective trial and cost analysis. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 2900-4	0.7	170
24	Intragastric acidification reduces the occurrence of false-negative urea breath test results in patients taking a proton pump inhibitor. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 1028-32	0.7	28
23	Images in clinical medicine. Pneumatosis coli and colonic intussusception. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 964	59.2	4
22	Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice. <i>Archives of Internal Medicine</i> , <b>2001</b> , 161, 2129-32		18
21	Gastric emptying characteristics of a novel ( <sup>13</sup> C)-octanoate-labeled muffin meal. <i>Journal of Clinical Gastroenterology</i> , <b>2001</b> , 32, 394-9	3	26
20	Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2000</b> , 14, 97-101	6.1	12
19	The channel occlusion technique: a novel method of retrieving polyps following snare resection. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 1608-9	0.7	10
18	Appropriate timing of the <sup>14</sup> C-urea breath test to establish eradication of Helicobacter pylori infection. <i>American Journal of Gastroenterology</i> , <b>2000</b> , 95, 1171-4	0.7	14
17	Accurate diagnosis of Helicobacter pylori. <sup>14</sup> C-urea breath test. <i>Gastroenterology Clinics of North America</i> , <b>2000</b> , 29, 895-902	4.4	20
16	Routine droperidol pre-medication improves sedation for ERCP. <i>Gastrointestinal Endoscopy</i> , <b>2000</b> , 52, 362-6	5.2	25
15	The <sup>13</sup> C-urea blood test accurately detects active Helicobacter pylori infection: a United States, multicenter trial. <i>American Journal of Gastroenterology</i> , <b>1999</b> , 94, 1522-4	0.7	17
14	A comparison of three fingerstick, whole blood antibody tests for Helicobacter pylori infection: a United States, multicenter trial. <i>American Journal of Gastroenterology</i> , <b>1999</b> , 94, 1512-6	0.7	12
13	Symptom status and the desire for Helicobacter pylori confirmatory testing after eradication therapy in patients with peptic ulcer disease. <i>American Journal of Medicine</i> , <b>1999</b> , 107, 133-6	2.4	18

12	Low- versus high-dose azithromycin triple therapy for <i>Helicobacter pylori</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1998</b> , 12, 1263-7	6.1	18
11	Pure cut electrocautery current for sphincterotomy causes less post-procedure pancreatitis than blended current. <i>Gastrointestinal Endoscopy</i> , <b>1998</b> , 47, 149-53	5.2	100
10	The ChemTrak Hp Chek fingerstick whole blood serology test for the detection of <i>Helicobacter pylori</i> infection. <i>American Journal of Gastroenterology</i> , <b>1998</b> , 93, 16-9	0.7	5
9	Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. <i>American Journal of Gastroenterology</i> , <b>1997</b> , 92, 446-50	0.7	67
8	Proton pump inhibitors and the urea breath test: how long is long enough?. <i>American Journal of Gastroenterology</i> , <b>1997</b> , 92, 720-1	0.7	10
7	Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for <i>Helicobacter pylori</i> infection: a randomized trial. <i>American Journal of Gastroenterology</i> , <b>1997</b> , 92, 1483-6	0.7	8
6	One-week therapy for <i>Helicobacter pylori</i> . A randomized trial of two treatment regimens. <i>Journal of Clinical Gastroenterology</i> , <b>1996</b> , 23, 170-3	3	3
5	Prolonged effect of omeprazole on the 14C-urea breath test. <i>American Journal of Gastroenterology</i> , <b>1996</b> , 91, 89-92	0.7	44
4	Octreotide reduces perception of rectal electrical stimulation by spinal afferent pathway inhibition. <i>American Journal of Physiology - Renal Physiology</i> , <b>1995</b> , 269, G821-6	5.1	12
3	Hyperglycemia alters perception of rectal distention and blunts the rectoanal inhibitory reflex in healthy volunteers. <i>Gastroenterology</i> , <b>1995</b> , 108, 1700-8	13.3	45
2	Possible nizatidine-induced subfulminant hepatic failure. <i>Journal of Clinical Gastroenterology</i> , <b>1995</b> , 20, 164-7	3	3
1	Angiodysplasia and von Willebrand's disease type IIB treated with estrogen/progesterone therapy. <i>American Journal of Hematology</i> , <b>1992</b> , 41, 276-9	7.1	21